The CaDDM clinical trial is funded
Based on strong preliminary data generated by Dr. Pittas and colleagues, the Vitamin D and Calcium Homeostasis for Prevention of Type 2 Diabetes (CaDDM) study is funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the Office of Dietary Supplements (ODS) of the National Institutes of Health (NIH). The CaDDM study is a double-blind, placebo-controlled randomized clinical trial to test the effects of vitamin D and/or calcium supplementation on disposition index, which is a measure of how well the pancreatic beta cells secrete insulin in response to a glucose load. The trial targets adults at risk for type 2 diabetes or with early type 2 diabetes (i.e., not requiring medications) randomized to receive 2,000 units/day of vitamin D3 and/or 800 mg/day of calcium carbonate (2×2 factorial design) for 4 months. The CaDDM study enrolls its first patient in September of 2007.